Wuxi

WuXi to go private as part of $3.3bn deal

WuXi to go private as part of $3.3bn deal

By Zachary Brennan

A group of investors, shareholders and executives of China-based CDMO WuXi are taking the company private in a deal worth about $3.3bn.

Tigermed Envy? WuXi may be eyeing a launch on Shenzhen exchange

Tigermed Envy? WuXi may be eyeing a launch on Shenzhen exchange

By Zachary Brennan

With WuXi pushing full steam ahead in its bid to go private, one expert says that the company may be envious of a competing CRO -- Hangzhou Tigermed, which is smaller than WuXi but valued at a higher price on the Shenzhen stock exchange.

WuXi offers more details on the complexity of CRO, CMO competition

WuXi offers more details on the complexity of CRO, CMO competition

By Zachary Brennan

Competition in the notoriously tight-lipped CRO (contract research organization) and CMO (contract manufacturing organization) industries is getting fiercer as outsourcing picks up, though that hasn’t stopped one Chinese company from revealing who it...

WuXi sells small share of CMO subsidiary for $28m

WuXi sells small share of CMO subsidiary for $28m

By Zachary Brennan

Chinese service provider WuXi PharmaTech has sold a 5.55% stake in its wholly owned CMO (contract manufacturing organization) subsidiary SynTheAll Pharmaceutical (STA) to members of STA’s and WuXi’s management for $28m.

CFDA accepts WuXi-MedImmune’s IND for new mAb

CFDA accepts WuXi-MedImmune’s IND for new mAb

By Zachary Brennan

The China Food and Drug Administration (CFDA) has accepted for review an Investigational New Drug (IND) application for WuXi and MedImmune's novel anti-IL6 monoclonal antibody (mAb) for rheumatoid arthritis. 

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers